Is Processa Pharmaceuticals Inc (PCSA) overvalued? · $5.9M cap
Processa Pharmaceuticals Inc (PCSA) is a biotechnology company listed on NASDAQ.
This page asks whether Processa Pharmaceuticals Inc (PCSA) looks expensive on cached numbers — not a short thesis.
Latest reported PCSA revenue for 2023-09-30 was $0. Net income was -$2.1M. PCSA currently screens at market cap $5.9M.
PCSA currently screens at market cap $5.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PCSA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PCSA stock page for the full model, not this heading.
Not investment advice.